BetterLife Pharma Inc. (BETRF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -3.19 Million CAD | 65.48% |
| 2023 | -9.23 Million CAD | 17.08% |
| 2022 | -9.95 Million CAD | -42.31% |
| 2021 | -7.79 Million CAD | -1.25% |
| 2020 | -7.73 Million CAD | -38.43% |
| 2019 | -5.58 Million CAD | -340.69% |
| 2018 | -1.19 Million CAD | 83.59% |
| 2017 | -7.58 Million CAD | 35.53% |
| 2016 | -14.51 Million CAD | -16688.74% |
| 2015 | -130.35 Thousand CAD | -57.31% |
| 2014 | -45.4 Thousand CAD | 49.12% |
| 2013 | -89.23 Thousand CAD | 75.11% |
| 2012 | -362.51 Thousand CAD | -113.09% |
| 2011 | -144.33 Thousand CAD | 2424.98% |
| 2010 | - CAD | 81.95% |
| 2009 | -652.7 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - CAD | 65.28% |
| 2024 Q3 | -156.58 Thousand CAD | 79.77% |
| 2024 Q1 | -673.84 Thousand CAD | -34.51% |
| 2024 Q4 | -730.25 Thousand CAD | -217.88% |
| 2024 Q2 | -1.09 Million CAD | -6.21% |
| 2023 Q2 | -1.35 Million CAD | 55.35% |
| 2023 Q1 | -3.04 Million CAD | -2.26% |
| 2023 Q4 | -715.21 Thousand CAD | 83.21% |
| 2023 Q3 | -4.25 Million CAD | -213.67% |
| 2023 FY | - CAD | 17.08% |
| 2022 Q3 | -2.15 Million CAD | 40.0% |
| 2022 FY | - CAD | -42.31% |
| 2022 Q2 | -3.59 Million CAD | -48.82% |
| 2022 Q1 | -2.41 Million CAD | 1.97% |
| 2022 Q4 | -2.97 Million CAD | -37.72% |
| 2021 Q3 | -2.77 Million CAD | -101.54% |
| 2021 FY | - CAD | -1.25% |
| 2021 Q1 | -1.02 Million CAD | -528.17% |
| 2021 Q2 | -1.37 Million CAD | -34.4% |
| 2021 Q4 | -2.46 Million CAD | 11.07% |
| 2020 Q3 | -2.31 Million CAD | 39.84% |
| 2020 Q2 | -3.84 Million CAD | -173.41% |
| 2020 Q1 | -1.4 Million CAD | -39.89% |
| 2020 FY | - CAD | -38.43% |
| 2020 Q4 | -163.01 Thousand CAD | 92.95% |
| 2019 Q4 | -1 Million CAD | 35.54% |
| 2019 Q2 | -1.44 Million CAD | 20.96% |
| 2019 Q3 | -1.55 Million CAD | -8.1% |
| 2019 Q1 | -1.82 Million CAD | -274.99% |
| 2019 FY | - CAD | -340.69% |
| 2018 Q2 | -300.59 Thousand CAD | -2.28% |
| 2018 FY | - CAD | 83.59% |
| 2018 Q4 | -486.72 Thousand CAD | -175.74% |
| 2018 Q3 | -176.51 Thousand CAD | 41.28% |
| 2018 Q1 | -293.9 Thousand CAD | 68.64% |
| 2017 FY | - CAD | 35.53% |
| 2017 Q1 | -4.14 Million CAD | 45.44% |
| 2017 Q4 | -937.13 Thousand CAD | -10.94% |
| 2017 Q2 | -1.37 Million CAD | 66.83% |
| 2017 Q3 | -844.7 Thousand CAD | 38.59% |
| 2016 Q4 | -7.6 Million CAD | -170330.72% |
| 2016 FY | - CAD | -16688.74% |
| 2016 Q1 | -1.44 Million CAD | -1996.42% |
| 2016 Q2 | -2.94 Million CAD | -103.46% |
| 2016 Q3 | -4460.00 CAD | 99.85% |
| 2015 Q3 | -16.54 Thousand CAD | 44.35% |
| 2015 FY | - CAD | -57.31% |
| 2015 Q1 | -101.34 Thousand CAD | -1113.68% |
| 2015 Q2 | -29.72 Thousand CAD | 70.67% |
| 2015 Q4 | 76.19 Thousand CAD | 560.56% |
| 2014 Q2 | -27.19 Thousand CAD | -141.75% |
| 2014 Q4 | 9998.00 CAD | 158.97% |
| 2014 Q3 | -16.95 Thousand CAD | 37.67% |
| 2014 Q1 | -11.25 Thousand CAD | -102.12% |
| 2014 FY | - CAD | 49.12% |
| 2013 Q2 | 51.97 Thousand CAD | 107.71% |
| 2013 FY | - CAD | 75.11% |
| 2013 Q1 | -674.33 Thousand CAD | -123.55% |
| 2013 Q3 | 2950.00 CAD | -94.32% |
| 2013 Q4 | 530.17 Thousand CAD | 17872.14% |
| 2012 Q3 | -465.83 Thousand CAD | -60.51% |
| 2012 Q2 | -290.22 Thousand CAD | 88.25% |
| 2012 FY | - CAD | -113.09% |
| 2012 Q4 | 2.86 Million CAD | 714.66% |
| 2012 Q1 | -2.46 Million CAD | -4607.51% |
| 2011 Q2 | -42.52 Thousand CAD | -57.19% |
| 2011 Q4 | -52.46 Thousand CAD | -159.92% |
| 2011 Q3 | -20.18 Thousand CAD | 52.53% |
| 2011 FY | - CAD | 2424.98% |
| 2011 Q1 | -27.05 Thousand CAD | -68.16% |
| 2010 Q4 | -16.08 Thousand CAD | -13.96% |
| 2010 Q2 | -75.96 Thousand CAD | -493.3% |
| 2010 FY | - CAD | 81.95% |
| 2010 Q3 | -14.11 Thousand CAD | 81.42% |
| 2010 Q1 | -12.8 Thousand CAD | 0.0% |
| 2009 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 95.507% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 46.171% |
| SQZ Biotechnologies Company | -64.14 Million USD | 95.024% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 81.627% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 103.394% |
| Mesoblast Limited | -62.38 Million USD | 94.885% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -107.77% |
| Genus plc | 73.7 Million USD | 104.33% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 51.729% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 10.024% |
| Marizyme, Inc. | -34.28 Million USD | 90.69% |
| ContraFect Corporation | -64.99 Million USD | 95.09% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 63.618% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 29.489% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -127.667% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -20.685% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -37.337% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -516.056% |
| Accustem Sciences Inc. | -3.74 Million USD | 14.813% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 93.382% |
| EV Biologics, Inc. | -1.26 Million USD | -151.864% |
| Q BioMed Inc. | -617.62 Thousand USD | -416.728% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 189.346% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -404.653% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -39.701% |
| Biomind Labs Inc. | -1.03 Million USD | -208.487% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 132.312% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 55.435% |
| Skye Bioscience, Inc. | -13.54 Million USD | 76.443% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -114.564% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -12665.816% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 17.838% |
| IMV Inc. | -35.52 Million USD | 91.016% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 79.89% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -27.558% |
| GB Sciences, Inc. | -1.41 Million USD | -124.768% |
| Alpha Cognition Inc. | -9.7 Million USD | 67.117% |
| HST Global, Inc. | -5303.00 USD | -60082.048% |
| CSL Limited | 4.78 Billion USD | 100.067% |
| Halberd Corporation | -74.27 Thousand USD | -4196.576% |
| Enzolytics Inc. | -2.12 Million USD | -50.396% |
| Resverlogix Corp. | -11.74 Million USD | 72.82% |
| Affymax, Inc. | -14.29 Million USD | 77.674% |
| SYBLEU INC | -141.57 Thousand USD | -2154.313% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -4.193% |
| argenx SE | -216.02 Million USD | 98.523% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 94.233% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 362.239% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -112.919% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 942.419% |
| AVAX Technologies, Inc. | -6.11 Million USD | 47.789% |
| Zenith Capital Corp. | -8.6 Million USD | 62.916% |
| Genscript Biotech Corporation | -248.71 Million USD | 98.717% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -18219.58% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -30.452% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1713.075% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 91.948% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -10.342% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -205.019% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 47563.623% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -82.369% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -66.143% |
| BioStem Technologies, Inc. | -7.55 Million USD | 57.749% |
| ONE Bio Corp. | 13.61 Million USD | 123.444% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1662.377% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -55.151% |
| Agentix Corp. | -1.37 Million USD | -132.655% |
| LadRx Corporation | 412.28 Thousand USD | 874.093% |
| Cell Source, Inc. | -4.27 Million USD | 25.303% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -769.083% |
| Regen BioPharma, Inc. | 1.46 Million USD | 317.705% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -240.622% |
| NovAccess Global Inc. | -1.03 Million USD | -208.414% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 136.046% |
| Itoco Inc. | -1.86 Million USD | -70.758% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -740.697% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -185.973% |
| Kadimastem Ltd | -2.62 Million USD | -21.608% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1234.499% |
| CytoDyn Inc. | -18.02 Million USD | 82.298% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3938.333% |
| Mobile Lads Corp. | -2.24 Million USD | -42.402% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -25997.424% |
| Qrons Inc. | -40.08 Thousand USD | -7862.511% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -557.113% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 705.092% |
| Rebus Holdings, Inc. | -951 Thousand USD | -235.589% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -200.511% |
| International Stem Cell Corporation | 202 Thousand USD | 1679.928% |
| Bioxytran, Inc. | -3.82 Million USD | 16.457% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5962.793% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -29.632% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 91.102% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -6992.12% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -16.562% |
| Neutra Corp. | -181.24 Thousand USD | -1660.831% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 84.169% |
| PureTech Health plc | -11.62 Million USD | 72.551% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 84.168% |
| IXICO plc | -707 Thousand USD | -351.408% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 58.472% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 93.399% |
| CSL Limited | 4.73 Billion USD | 100.067% |
| Cellectis S.A. | -92.63 Million USD | 96.555% |